© 1999 American Heart Association, Inc.
Original Contributions |
Interaction Between the G20210A Mutation of the Prothrombin Gene and Oral Contraceptive Use in Deep Vein Thrombosis
From Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine (I.M., P.B., S.A., P.M.M.), and Epidemiology Unit (E.T.), IRCCS Maggiore Hospital, University of Milan, Italy
Correspondence to Ida Martinelli, MD, PhD, Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital, Via Pace 9, 20122 Milano, Italy. E-mail martin{at}polic.cilea.it
Abstract—Single-point mutations in the gene coding for prothrombin (factor II:A20210) or factor V (factor V:A1691) are associated with an increased risk of venous thromboembolism. The use of oral contraceptives is also a strong and independent risk factor for the disease, and the interaction between factor V:A1691 and oral contraceptives greatly increases the risk. No information is available about the interaction between oral contraceptives and mutant prothrombin. We investigated 148 women with a first, objectively confirmed episode of deep vein thrombosis and 277 healthy women as controls. Fourteen patients (9.4%) were carriers of factor II:A20210, 24 (16.2%) of factor V:A1691, and 4 (2.7%) of both defects. Among controls, the prevalence was 2.5% for either factor II:A20210 or factor V:A1691, and there was no carrier of both the mutations. The relative risk of thrombosis was 6-fold for factor II:A20210 and 9-fold for factor V:A1691. The most prevalent circumstantial risk factor in patients and the only one observed in controls was oral contraceptive use, which per se conferred a 6-fold increased risk of thrombosis. The risk increased to 16.3 and 20.0 when women with factor II:A20210 or factor V:A1691 who used oral contraceptives were compared with noncarriers and nonusers. These figures indicate a multiplicative interaction between the genetic risk factors and oral contraceptives. No difference in the type of oral contraceptives was observed between patients and controls, those of third generation being the most frequently used (73% and 80%). We conclude that carriers of the prothrombin mutation who use oral contraceptives have a markedly increased risk of deep vein thrombosis, much higher than the risk conferred by either factor alone.
Key Words: venous thrombosis • prothrombin mutation • factor V mutation • oral contraceptives
This article has been cited by other articles:
 |
|
 |
|
  P. Dulicek, J. Maly, M. Pecka, M. Beranek, E. Cermakova, and R. Maly Venous Thromboembolism in Young Female While on Oral Contraceptives: High Frequency of Inherited Thrombophilia and Analysis of Thrombotic Events in 400 Czech Women Clinical and Applied Thrombosis/Hemostasis, October 1, 2009; 15(5): 567 - 573. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Rathbun Venous thromboembolism in women Vascular Medicine, August 1, 2008; 13(3): 255 - 266. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Navarro, P. Medina, Y. Mira, A. Estelles, P. Villa, F. Ferrando, A. Vaya, R. M. Bertina, and F. Espana Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation Haematologica, June 1, 2008; 93(6): 885 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Franchini and P. M. Mannucci Interactions between genotype and phenotype in bleeding and thrombosis Haematologica, May 1, 2008; 93(5): 649 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. W. van Vlijmen, J.-L. P. Brouwer, N. J. G. M. Veeger, T. K. A. B. Eskes, P. A. de Graeff, and J. van der Meer Oral Contraceptives and the Absolute Risk of Venous Thromboembolism in Women With Single or Multiple Thrombophilic Defects: Results From a Retrospective Family Cohort Study Arch Intern Med, February 12, 2007; 167(3): 282 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bosler, J. Mattson, and D. Crisan Phenotypic Heterogeneity in Patients with Homozygous Prothrombin 20210AA Genotype: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2006; 8(4): 420 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. R. Rosendaal Venous Thrombosis: The Role of Genes, Environment, and Behavior Hematology, January 1, 2005; 2005(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. V. Gomes and S. R. Deitcher Risk of Venous Thromboembolic Disease Associated With Hormonal Contraceptives and Hormone Replacement Therapy: A Clinical Review Arch Intern Med, October 11, 2004; 164(18): 1965 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Bank, E. J. Libourel, S. Middeldorp, E. C. M. van Pampus, M. M. W. Koopman, K. Hamulyak, M. H. Prins, J. van der Meer, and H. R. Buller Prothrombin 20210A Mutation: A Mild Risk Factor for Venous Thromboembolism but Not for Arterial Thrombotic Disease and Pregnancy-Related Complications in a Family Study Arch Intern Med, September 27, 2004; 164(17): 1932 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Varga and S. Moll Prothrombin 20210 Mutation (Factor II Mutation) Circulation, July 20, 2004; 110(3): e15 - e18. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Duggan, K. Marriott, R. Edwards, and J. Cuzick Inherited and Acquired Risk Factors for Venous Thromboembolic Disease Among Women Taking Tamoxifen to Prevent Breast Cancer J. Clin. Oncol., October 1, 2003; 21(19): 3588 - 3593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Cosmi, C. Legnani, F. Bernardi, S. Coccheri, and G. Palareti Role of Family History in Identifying Women With Thrombophilia and Higher Risk of Venous Thromboembolism During Oral Contraception Arch Intern Med, May 12, 2003; 163(9): 1105 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Girolami, L. Spiezia, F. Vianello, B. Girolami, and F. Fabris Changes in Prescription Patterns of Oral Contraceptives in a Northern Italian Province: Relation With Venous Thromboembolism Clinical and Applied Thrombosis/Hemostasis, April 1, 2003; 9(2): 125 - 130. [Abstract] [PDF]
|
|
|
|
 |
|
 J. L. Anderson, J. F. Carlquist, B. D. Home, and J. B. Muhlestein Cardiovascular Pharmacogenomics: Current Status, Future Prospects Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 71 - 83. [Abstract] [PDF]
|
|
|
|
|
|
S. R Deitcher and M. P. Gomes Hypercoagulable state testing and malignancy screening following venous thromboembolic events Vascular Medicine, February 1, 2003; 8(1): 33 - 46. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Legnani, G. Palareti, G. Guazzaloca, B. Cosmi, B. Lunghi, F. Bernardi, and S. Coccheri Venous thromboembolism in young women. Role of thrombophilic mutations and oral contraceptive use Eur. Heart J., June 2, 2002; 23(12): 984 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Girolami, L. Spiezia, B. Girolami, and F. Vianello Tentative Guidelines and Practical Suggestions to Avoid Venous Thromboembolism During Oral Contraceptive Therapy Clinical and Applied Thrombosis/Hemostasis, April 1, 2002; 8(2): 97 - 102. [Abstract] [PDF]
|
|
|
|
|
|
A. Girolami, L. Spiezia, F. Rossi, and E. Zanon Oral Contraceptives and Venous Thromboembolism: Which Are the Safest Preparations Available? Clinical and Applied Thrombosis/Hemostasis, April 1, 2002; 8(2): 157 - 162. [Abstract] [PDF]
|
|
|
|
 |
|
 F.R. Rosendaal, F.M. Helmerhorst, and J.P. Vandenbroucke Female Hormones and Thrombosis Arterioscler Thromb Vasc Biol, February 1, 2002; 22(2): 201 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Aznar and Y. Mira Prothrombotic Activity of Oral Contraceptives in Patients with Congenital Thrombophilia Clinical and Applied Thrombosis/Hemostasis, January 1, 2002; 8(1): 91 - 92. [PDF]
|
|
|
|
 |
|
 A. Tripodi and P. M. Mannucci Laboratory Investigation of Thrombophilia Clin. Chem., September 1, 2001; 47(9): 1597 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Kemmeren, A. Algra, and D. E Grobbee Third generation oral contraceptives and risk of venous thrombosis: meta-analysis BMJ, July 21, 2001; 323(7305): 131 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Vandenbroucke, J. Rosing, K. W.M. Bloemenkamp, S. Middeldorp, F. M. Helmerhorst, B. N. Bouma, and F. R. Rosendaal Oral Contraceptives and the Risk of Venous Thrombosis N. Engl. J. Med., May 17, 2001; 344(20): 1527 - 1535. [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Botto and M. J. Khoury Commentary: Facing the Challenge of Gene-Environment Interaction: The Two-by-Four Table and Beyond Am. J. Epidemiol., May 15, 2001; 153(10): 1016 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Cosmi, C. Legnani, F. Bernardi, S. Coccheri, and G. Palareti Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study BMJ, April 28, 2001; 322(7293): 1024 - 1025. [Full Text]
|
|
|
|
|
|
B. G. Macik, J. H. Rand, and B. A. Konkle Thrombophilia: What's a Practitioner to Do? Hematology, January 1, 2001; 2001(1): 322 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mira, J. Aznar, A. Estelles, A. Vaya, P. Villa, and F. Ferrando State-of-the-Art Review : Congenital and Acquired Thrombotic Risk Factors in Women Using Oral Contraceptives: Clinical Aspects Clinical and Applied Thrombosis/Hemostasis, July 1, 2000; 6(3): 162 - 168. [Abstract] [PDF]
|
|